MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia
Copy number alterations (CNAs) at 58 different loci have been investigated in 95 bone marrow or peripheral blood samples from patients with chronic myeloid leukemia (CML) or pediatric acute lymphoblastic leukemia (pALL) using multiplex ligation-dependent probe amplification (MLPA). In all but one ca...
Gespeichert in:
| Veröffentlicht in: | Cancer genetics 2012-09, Vol.205 (9), p.465-469 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 469 |
|---|---|
| container_issue | 9 |
| container_start_page | 465 |
| container_title | Cancer genetics |
| container_volume | 205 |
| creator | Alpár, Donát de Jong, Danielle Savola, Suvi Yigittop, HaciAli Kajtár, Béla Kereskai, László Pajor, László Szuhai, Károly |
| description | Copy number alterations (CNAs) at 58 different loci have been investigated in 95 bone marrow or peripheral blood samples from patients with chronic myeloid leukemia (CML) or pediatric acute lymphoblastic leukemia (pALL) using multiplex ligation-dependent probe amplification (MLPA). In all but one case, the CNA profile correctly distinguished patients with CML who were in chronic phase from those in lymphoblast crisis. Within the chronic phase group, we could not separate patients resistant to imatinib therapy from those who were good responders. In our investigation of patients with pALL, a panel of MLPA probes broader than ever before was applied. Paired diagnostic and relapse samples from patients with pALL demonstrated clonally related or independent dominant clones, suggesting the presence of a pre-leukemic cell group. Identification of the origin of cell populations dominating at relapse will have a great effect on future treatment strategies. In summary, we have demonstrated the versatility of MLPA by using this cost-effective technique for two new applications. |
| doi_str_mv | 10.1016/j.cancergen.2012.05.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1125240462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S221077621200138X</els_id><sourcerecordid>1125240462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-39173c571b80f3ba5c42185187a92f99ddce2a58cd483a56c4da9a3dff891b153</originalsourceid><addsrcrecordid>eNqNks1u1DAUhSMEolXpK4CXbCb4J54kG6RRRaHSIJAAiZ11x76Z8dSJg-0UzXPxgnWYdhbdgL2wpXvOd2WfWxRvGC0ZZct3-1LDoDFscSg5ZbyksqS0flacc87ooq5r-vx0X_Kz4jLGPc2rkrSpxcvijPNW5N2eF38-r7-uiI0EyOh_Y-gmR5L3jnQ-EIMJdbLDlrhDP-78xkFMVpMUYIhZ0EOyfiB2IHoX_JAr_QGdt4Y4nG6xt0BgMCTgHYKbMWmHRDs_gCM-2G02-i6XHYwRZ8yIxkIKGQR6Svik7SP0VfGiAxfx8uG8KH5cf_h-9Wmx_vLx5mq1XuhKtmkhWlYLLWu2aWgnNiB1xVkjWVNDy7u2NUYjB9loUzUC5FJXBloQpuualm2YFBfF2yN3DP7XhDGp3kaNzsGAfoqKMS55Rasl_7eUirppePuXWh-lOvgYA3ZqDLaHcMgiNeer9uqUr5rzVVSqnG92vn5oMm16NCffY5pZsDoKMP_KncWgoraYUcaGHKQy3v5Hk_dPGDpHZzW4Wzxg3Psp5Pjyi1TMHvVtHrN5yhinlInmp7gH4-rTog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1037882915</pqid></control><display><type>article</type><title>MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Alpár, Donát ; de Jong, Danielle ; Savola, Suvi ; Yigittop, HaciAli ; Kajtár, Béla ; Kereskai, László ; Pajor, László ; Szuhai, Károly</creator><creatorcontrib>Alpár, Donát ; de Jong, Danielle ; Savola, Suvi ; Yigittop, HaciAli ; Kajtár, Béla ; Kereskai, László ; Pajor, László ; Szuhai, Károly</creatorcontrib><description>Copy number alterations (CNAs) at 58 different loci have been investigated in 95 bone marrow or peripheral blood samples from patients with chronic myeloid leukemia (CML) or pediatric acute lymphoblastic leukemia (pALL) using multiplex ligation-dependent probe amplification (MLPA). In all but one case, the CNA profile correctly distinguished patients with CML who were in chronic phase from those in lymphoblast crisis. Within the chronic phase group, we could not separate patients resistant to imatinib therapy from those who were good responders. In our investigation of patients with pALL, a panel of MLPA probes broader than ever before was applied. Paired diagnostic and relapse samples from patients with pALL demonstrated clonally related or independent dominant clones, suggesting the presence of a pre-leukemic cell group. Identification of the origin of cell populations dominating at relapse will have a great effect on future treatment strategies. In summary, we have demonstrated the versatility of MLPA by using this cost-effective technique for two new applications.</description><identifier>ISSN: 2210-7762</identifier><identifier>EISSN: 2210-7770</identifier><identifier>DOI: 10.1016/j.cancergen.2012.05.007</identifier><identifier>PMID: 22939399</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute lymphatic leukemia ; acute lymphoblastic leukemia ; Antineoplastic Agents ; Benzamides ; Cell Transformation, Neoplastic - genetics ; Cell Transformation, Neoplastic - immunology ; Cell Transformation, Neoplastic - pathology ; Child ; chronic myeloid leukemia ; Clonal Evolution ; clonal origin ; Cohort Studies ; DNA Copy Number Variations ; Hematology, Oncology and Palliative Medicine ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Lymphocyte Activation ; Medical Education ; MLPA ; Nucleic Acid Amplification Techniques - methods ; Piperazines ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Pyrimidines ; Recurrence ; relapse</subject><ispartof>Cancer genetics, 2012-09, Vol.205 (9), p.465-469</ispartof><rights>2012</rights><rights>Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-39173c571b80f3ba5c42185187a92f99ddce2a58cd483a56c4da9a3dff891b153</citedby><cites>FETCH-LOGICAL-c459t-39173c571b80f3ba5c42185187a92f99ddce2a58cd483a56c4da9a3dff891b153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cancergen.2012.05.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27913,27914,45984</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22939399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alpár, Donát</creatorcontrib><creatorcontrib>de Jong, Danielle</creatorcontrib><creatorcontrib>Savola, Suvi</creatorcontrib><creatorcontrib>Yigittop, HaciAli</creatorcontrib><creatorcontrib>Kajtár, Béla</creatorcontrib><creatorcontrib>Kereskai, László</creatorcontrib><creatorcontrib>Pajor, László</creatorcontrib><creatorcontrib>Szuhai, Károly</creatorcontrib><title>MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia</title><title>Cancer genetics</title><addtitle>Cancer Genet</addtitle><description>Copy number alterations (CNAs) at 58 different loci have been investigated in 95 bone marrow or peripheral blood samples from patients with chronic myeloid leukemia (CML) or pediatric acute lymphoblastic leukemia (pALL) using multiplex ligation-dependent probe amplification (MLPA). In all but one case, the CNA profile correctly distinguished patients with CML who were in chronic phase from those in lymphoblast crisis. Within the chronic phase group, we could not separate patients resistant to imatinib therapy from those who were good responders. In our investigation of patients with pALL, a panel of MLPA probes broader than ever before was applied. Paired diagnostic and relapse samples from patients with pALL demonstrated clonally related or independent dominant clones, suggesting the presence of a pre-leukemic cell group. Identification of the origin of cell populations dominating at relapse will have a great effect on future treatment strategies. In summary, we have demonstrated the versatility of MLPA by using this cost-effective technique for two new applications.</description><subject>Acute lymphatic leukemia</subject><subject>acute lymphoblastic leukemia</subject><subject>Antineoplastic Agents</subject><subject>Benzamides</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>Cell Transformation, Neoplastic - immunology</subject><subject>Cell Transformation, Neoplastic - pathology</subject><subject>Child</subject><subject>chronic myeloid leukemia</subject><subject>Clonal Evolution</subject><subject>clonal origin</subject><subject>Cohort Studies</subject><subject>DNA Copy Number Variations</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Lymphocyte Activation</subject><subject>Medical Education</subject><subject>MLPA</subject><subject>Nucleic Acid Amplification Techniques - methods</subject><subject>Piperazines</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Pyrimidines</subject><subject>Recurrence</subject><subject>relapse</subject><issn>2210-7762</issn><issn>2210-7770</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNks1u1DAUhSMEolXpK4CXbCb4J54kG6RRRaHSIJAAiZ11x76Z8dSJg-0UzXPxgnWYdhbdgL2wpXvOd2WfWxRvGC0ZZct3-1LDoDFscSg5ZbyksqS0flacc87ooq5r-vx0X_Kz4jLGPc2rkrSpxcvijPNW5N2eF38-r7-uiI0EyOh_Y-gmR5L3jnQ-EIMJdbLDlrhDP-78xkFMVpMUYIhZ0EOyfiB2IHoX_JAr_QGdt4Y4nG6xt0BgMCTgHYKbMWmHRDs_gCM-2G02-i6XHYwRZ8yIxkIKGQR6Svik7SP0VfGiAxfx8uG8KH5cf_h-9Wmx_vLx5mq1XuhKtmkhWlYLLWu2aWgnNiB1xVkjWVNDy7u2NUYjB9loUzUC5FJXBloQpuualm2YFBfF2yN3DP7XhDGp3kaNzsGAfoqKMS55Rasl_7eUirppePuXWh-lOvgYA3ZqDLaHcMgiNeer9uqUr5rzVVSqnG92vn5oMm16NCffY5pZsDoKMP_KncWgoraYUcaGHKQy3v5Hk_dPGDpHZzW4Wzxg3Psp5Pjyi1TMHvVtHrN5yhinlInmp7gH4-rTog</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Alpár, Donát</creator><creator>de Jong, Danielle</creator><creator>Savola, Suvi</creator><creator>Yigittop, HaciAli</creator><creator>Kajtár, Béla</creator><creator>Kereskai, László</creator><creator>Pajor, László</creator><creator>Szuhai, Károly</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20120901</creationdate><title>MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia</title><author>Alpár, Donát ; de Jong, Danielle ; Savola, Suvi ; Yigittop, HaciAli ; Kajtár, Béla ; Kereskai, László ; Pajor, László ; Szuhai, Károly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-39173c571b80f3ba5c42185187a92f99ddce2a58cd483a56c4da9a3dff891b153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acute lymphatic leukemia</topic><topic>acute lymphoblastic leukemia</topic><topic>Antineoplastic Agents</topic><topic>Benzamides</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>Cell Transformation, Neoplastic - immunology</topic><topic>Cell Transformation, Neoplastic - pathology</topic><topic>Child</topic><topic>chronic myeloid leukemia</topic><topic>Clonal Evolution</topic><topic>clonal origin</topic><topic>Cohort Studies</topic><topic>DNA Copy Number Variations</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Lymphocyte Activation</topic><topic>Medical Education</topic><topic>MLPA</topic><topic>Nucleic Acid Amplification Techniques - methods</topic><topic>Piperazines</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Pyrimidines</topic><topic>Recurrence</topic><topic>relapse</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alpár, Donát</creatorcontrib><creatorcontrib>de Jong, Danielle</creatorcontrib><creatorcontrib>Savola, Suvi</creatorcontrib><creatorcontrib>Yigittop, HaciAli</creatorcontrib><creatorcontrib>Kajtár, Béla</creatorcontrib><creatorcontrib>Kereskai, László</creatorcontrib><creatorcontrib>Pajor, László</creatorcontrib><creatorcontrib>Szuhai, Károly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Cancer genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alpár, Donát</au><au>de Jong, Danielle</au><au>Savola, Suvi</au><au>Yigittop, HaciAli</au><au>Kajtár, Béla</au><au>Kereskai, László</au><au>Pajor, László</au><au>Szuhai, Károly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia</atitle><jtitle>Cancer genetics</jtitle><addtitle>Cancer Genet</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>205</volume><issue>9</issue><spage>465</spage><epage>469</epage><pages>465-469</pages><issn>2210-7762</issn><eissn>2210-7770</eissn><abstract>Copy number alterations (CNAs) at 58 different loci have been investigated in 95 bone marrow or peripheral blood samples from patients with chronic myeloid leukemia (CML) or pediatric acute lymphoblastic leukemia (pALL) using multiplex ligation-dependent probe amplification (MLPA). In all but one case, the CNA profile correctly distinguished patients with CML who were in chronic phase from those in lymphoblast crisis. Within the chronic phase group, we could not separate patients resistant to imatinib therapy from those who were good responders. In our investigation of patients with pALL, a panel of MLPA probes broader than ever before was applied. Paired diagnostic and relapse samples from patients with pALL demonstrated clonally related or independent dominant clones, suggesting the presence of a pre-leukemic cell group. Identification of the origin of cell populations dominating at relapse will have a great effect on future treatment strategies. In summary, we have demonstrated the versatility of MLPA by using this cost-effective technique for two new applications.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22939399</pmid><doi>10.1016/j.cancergen.2012.05.007</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-7762 |
| ispartof | Cancer genetics, 2012-09, Vol.205 (9), p.465-469 |
| issn | 2210-7762 2210-7770 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1125240462 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Acute lymphatic leukemia acute lymphoblastic leukemia Antineoplastic Agents Benzamides Cell Transformation, Neoplastic - genetics Cell Transformation, Neoplastic - immunology Cell Transformation, Neoplastic - pathology Child chronic myeloid leukemia Clonal Evolution clonal origin Cohort Studies DNA Copy Number Variations Hematology, Oncology and Palliative Medicine Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Lymphocyte Activation Medical Education MLPA Nucleic Acid Amplification Techniques - methods Piperazines Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Pyrimidines Recurrence relapse |
| title | MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A26%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MLPA%20is%20a%20powerful%20tool%20for%20detecting%20lymphoblastic%20transformation%20in%20chronic%20myeloid%20leukemia%20and%20revealing%20the%20clonal%20origin%20of%20relapse%20in%20pediatric%20acute%20lymphoblastic%20leukemia&rft.jtitle=Cancer%20genetics&rft.au=Alp%C3%A1r,%20Don%C3%A1t&rft.date=2012-09-01&rft.volume=205&rft.issue=9&rft.spage=465&rft.epage=469&rft.pages=465-469&rft.issn=2210-7762&rft.eissn=2210-7770&rft_id=info:doi/10.1016/j.cancergen.2012.05.007&rft_dat=%3Cproquest_cross%3E1125240462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1037882915&rft_id=info:pmid/22939399&rft_els_id=S221077621200138X&rfr_iscdi=true |